Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1985-04-19
1986-11-25
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514914, A61K 31445
Patent
active
046249575
ABSTRACT:
Retinal edema, in particular cystoid macular edema, is prevented or treated by administering to the patient afflicted with retinal edema or in danger of experiencing retinal edema an amount of a dopaminergic antagonist effective to reduce the edema. A preferred dopaminergic antagonist is haloperidol. The activity of the dopaminergic antagonist may be potentiated by concurrent administration of ascorbic acid.
REFERENCES:
patent: 4088755 (1978-05-01), Inanaga et al.
patent: 4166853 (1979-09-01), McCall
Remington's Pharmaceutical Sciences, 16th Ed., A. Osol, Ed., Mack's Publishing Co., Easton, Pa. (1980), pp. 1029-1037.
Chem. Abst., 82:93297h (1975)--Tuck.
Chem. Abst., 87:3625q (1977)--Tso et al.
Chem. Abst., 88:32029z (1978)--Scatton et al.
Chem. Abst., 89:12149f (1978)--Lapinet et al.
Chem. Abst., 93:143,069k (1980)--Magnistretti et al.
Chem. Abst., 101:48,632p (1984)--Chion.
Chem. Abst., 101:108,722s (1984)--Sears.
LandOfFree
Treatment and prevention of retinal edema with dopaminergic anta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of retinal edema with dopaminergic anta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of retinal edema with dopaminergic anta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1158676